GlobeNewswire: Stemline Therapeutics, Inc. Contains the last 10 of 202 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:12:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/05/04/2026614/0/en/Menarini-Group-to-Acquire-Stemline-Therapeutics-in-Transaction-Valued-at-Up-to-677-Million.html?f=22&fvtc=4&fvtv=18378Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million2020-05-04T11:00:00Z<![CDATA[FLORENCE, Italy and NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.]]>https://www.globenewswire.com/news-release/2020/03/13/2000563/0/en/Stemline-Therapeutics-Reports-Fourth-Quarter-2019-Financial-Results.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results2020-03-13T20:45:44Z<![CDATA[NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today reported financial results and business highlights for the fourth quarter ended December 31, 2019.]]>https://www.globenewswire.com/news-release/2020/03/11/1999021/0/en/Stemline-Therapeutics-to-Host-Conference-Call-on-Fourth-Quarter-2019-Financial-Results-on-March-16-2020.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 20202020-03-11T20:05:00Z<![CDATA[NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the company will host a conference call and webcast on Monday, March 16, 2020 at 8:00 a.m. ET to report its fourth quarter 2019 financial results and other business highlights.]]>https://www.globenewswire.com/news-release/2020/02/26/1990863/0/en/Stemline-Therapeutics-to-Present-at-the-Cowen-40th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference2020-02-26T12:30:00Z<![CDATA[NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that management will present at the Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 12:00 PM ET at the Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.]]>https://www.globenewswire.com/news-release/2020/01/13/1969894/0/en/Stemline-Therapeutics-Announces-Preliminary-2019-Net-Revenues-for-ELZONRIS-tagraxofusp-and-Highlights-Commercial-and-Clinical-Growth-Drivers.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers2020-01-13T21:15:00Z<![CDATA[NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net revenues for 2019, as well as outlined key BPDCN market successes and upcoming commercial and clinical milestones.]]>https://www.globenewswire.com/news-release/2020/01/08/1968110/0/en/Stemline-Therapeutics-to-Present-at-the-38th-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference2020-01-08T21:15:00Z<![CDATA[NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that management will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 9:30 AM PT at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.]]>https://www.globenewswire.com/news-release/2019/12/10/1958530/0/en/Stemline-Therapeutics-Recaps-ELZONRIS-Clinical-Data-Presentations-in-Patients-with-Myelofibrosis-oral-presentation-and-Multiple-Myeloma-at-the-61st-American-Society-of-Hematology-A.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting2019-12-10T13:00:00Z<![CDATA[NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented data from ELZONRIS® (tagraxofusp) Phase 1/2 clinical trials in myelofibrosis (oral presentation) and multiple myeloma, at the 2019 ASH annual meeting. The presentations are now available on the Stemline website, www.stemline.com, under the Scientific Presentations tab. Highlights of results are presented below.]]>https://www.globenewswire.com/news-release/2019/12/06/1957501/0/en/Stemline-Therapeutics-Names-Robert-M-Francomano-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer2019-12-06T23:30:00Z<![CDATA[NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial Officer.]]>https://www.globenewswire.com/news-release/2019/12/06/1957256/0/en/Stemline-Therapeutics-Highlights-Three-ELZONRIS-Presentations-Including-an-Oral-Presentation-in-Myelofibrosis-at-Upcoming-ASH-Meeting.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting2019-12-06T12:00:00Z<![CDATA[NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS (tagraxofusp), presentations, including an oral presentation of ELZONRIS clinical data in myelofibrosis, at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, that is being held from December 7-10 in Orlando, FL.]]>https://www.globenewswire.com/news-release/2019/11/29/1954181/0/en/Stemline-Therapeutics-to-Present-at-Piper-Jaffray-s-31st-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=18378Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference2019-11-29T18:05:00Z<![CDATA[NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Stemline management will present at Piper Jaffray’s 31st Annual Healthcare Conference on Tuesday, December 3rd at 1:30 PM EST at the Lotte New York Palace Hotel in New York City. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.]]>